Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2013

View Archived Issues

RespiVert presents results for the novel PI3K-gamma/delta inhibitor

Researchers identify novel plasma miRNA biomarkers for the diagnosis and prognosis of AAAs

Pfizer designs approach to develop potent brain-specific PET tracers

Novel RNAi therapeutics presented by Gradalis

Calimmune presents preclinical results for its anti-HIV lentiviral vector gene therapy

Targacept reports commencement of phase IIb TC-5214 study

Atopix receives U.K. Biomedical Catalyst grant

Novel PARP-1 inhibitors created at IMPACT Therapeutics

GlaxoSmithKline acquires vaccine developer Okairos

New IRAK-4 inhibitors designed by Merck & Co.

NICE issues final draft guidance recommending selective dapagliflozin use

AbbVie introduces high-dose Creon capsules in U.S.

Beijing Drug Administration accepts Sinovac's filing for EV71 vaccine candidate

Array BioPharma patents novel GPR119 receptor agonists

Encouraging topline results seen in phase II ofatumumab study

Chinese researchers report new cancer therapeutics

Idenix begins phase II study of all-oral combination of simeprevir and samatasvir for HCV

Researchers at Eli Lilly disclose novel retinoid RAR-gamma receptor antagonists

Novan reports promising findings from phase I study of acne treatment

Phase II trial to evaluate Immunovaccine's DPX-Survivac in glioblastoma

SBIR grant awarded to Orphagen for the development of novel small molecules

NEOMED and AstraZeneca expand strategic partnership

BioMarin's applications for Vimizim accepted by both FDA and EMA

FDA lifts clinical hold on phase II study of PharmAthene's anthrax vaccine

Endo Pharmaceuticals receives complete response letter from FDA regarding Aveed NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...